The FSR Pilot Grant program, initiated in 2018, seeks to fund innovative research in both clinical and basic science settings ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

"Our discovery of elevated ILC1s in sarcoidosis patients opens exciting possibilities for faster diagnosis, better disease monitoring, and potentially new therapeutic strategies." Dr. Claire M.

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish Sati from the ...

A study of a subset of patients in the ACCESS study showed that there was a delay in making the diagnosis of sarcoidosis, even when patients presented with pulmonary symptoms. The role of the ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT™ study in ...

Cardiac sarcoidosis and ACM genetic variants coexist with distinct features, highlighting the need for refined clinical ...